Cargando…
Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases
PURPOSE: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. METHODS: Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587245/ https://www.ncbi.nlm.nih.gov/pubmed/28913517 http://dx.doi.org/10.1016/j.joco.2017.01.005 |
_version_ | 1783261958079774720 |
---|---|
author | HodjatJalali, Kamran Mehravaran, Shiva Faghihi, Hooshang Hashemi, Hassan Kazemi, Pegah Rastad, Hadith |
author_facet | HodjatJalali, Kamran Mehravaran, Shiva Faghihi, Hooshang Hashemi, Hassan Kazemi, Pegah Rastad, Hadith |
author_sort | HodjatJalali, Kamran |
collection | PubMed |
description | PURPOSE: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. METHODS: Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) received a single dose intravitreal injection of 0.05 ml ziv-aflibercept (1.25 mg). Visual acuity, spectral domain optical coherence tomography (SD-OCT) activity, and possible side effects were assessed before and at 1 week and 1 month after the intervention. RESULTS: At 1 month after treatment, mean central macular thickness (CMT) significantly decreased from 531.09 μm to 339.5 μm (P < 0.001), and no signs of side effects were observed in any subject. All patients responded to treatment in terms of reduction in CMT. The improvement in visual acuity was statistically non-significant. CONCLUSION: Our findings suggest that a single dose intravitreal injection of ziv-aflibercept may have acceptable relative safety and efficacy in the treatment of patients with intraocular vascular disease. The trial was registered in the Iranian Registry of Clinical Trials (IRCT2015081723651N1). |
format | Online Article Text |
id | pubmed-5587245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-55872452017-09-14 Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases HodjatJalali, Kamran Mehravaran, Shiva Faghihi, Hooshang Hashemi, Hassan Kazemi, Pegah Rastad, Hadith J Curr Ophthalmol Brief Report PURPOSE: To investigate the short-term outcomes after intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases. METHODS: Thirty-four eyes of 29 patients with age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO) received a single dose intravitreal injection of 0.05 ml ziv-aflibercept (1.25 mg). Visual acuity, spectral domain optical coherence tomography (SD-OCT) activity, and possible side effects were assessed before and at 1 week and 1 month after the intervention. RESULTS: At 1 month after treatment, mean central macular thickness (CMT) significantly decreased from 531.09 μm to 339.5 μm (P < 0.001), and no signs of side effects were observed in any subject. All patients responded to treatment in terms of reduction in CMT. The improvement in visual acuity was statistically non-significant. CONCLUSION: Our findings suggest that a single dose intravitreal injection of ziv-aflibercept may have acceptable relative safety and efficacy in the treatment of patients with intraocular vascular disease. The trial was registered in the Iranian Registry of Clinical Trials (IRCT2015081723651N1). Elsevier 2017-03-11 /pmc/articles/PMC5587245/ /pubmed/28913517 http://dx.doi.org/10.1016/j.joco.2017.01.005 Text en Copyright © 2017, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Brief Report HodjatJalali, Kamran Mehravaran, Shiva Faghihi, Hooshang Hashemi, Hassan Kazemi, Pegah Rastad, Hadith Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases |
title | Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases |
title_full | Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases |
title_fullStr | Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases |
title_full_unstemmed | Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases |
title_short | Intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases |
title_sort | intravitreal injection of ziv-aflibercept in the treatment of choroidal and retinal vascular diseases |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5587245/ https://www.ncbi.nlm.nih.gov/pubmed/28913517 http://dx.doi.org/10.1016/j.joco.2017.01.005 |
work_keys_str_mv | AT hodjatjalalikamran intravitrealinjectionofzivafliberceptinthetreatmentofchoroidalandretinalvasculardiseases AT mehravaranshiva intravitrealinjectionofzivafliberceptinthetreatmentofchoroidalandretinalvasculardiseases AT faghihihooshang intravitrealinjectionofzivafliberceptinthetreatmentofchoroidalandretinalvasculardiseases AT hashemihassan intravitrealinjectionofzivafliberceptinthetreatmentofchoroidalandretinalvasculardiseases AT kazemipegah intravitrealinjectionofzivafliberceptinthetreatmentofchoroidalandretinalvasculardiseases AT rastadhadith intravitrealinjectionofzivafliberceptinthetreatmentofchoroidalandretinalvasculardiseases |